Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Quantum Biopharma ( (TSE:QNTM) ) has provided an update.
On December 6, 2025, Quantum BioPharma Ltd. announced its decision to terminate the At The Market Offering Agreement with H.C. Wainwright & Co., LLC, effective December 20, 2025. This decision means the company will no longer sell class B subordinate voting shares under the agreement, which initially allowed for the sale of shares up to $21,225,000. Notably, no shares had been sold under this agreement as of the announcement date.
More about Quantum Biopharma
Quantum BioPharma Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is primarily engaged in offering biopharmaceutical products and services with a market focus on advancing healthcare solutions.
YTD Price Performance: 141.37%
Average Trading Volume: 4,982
Technical Sentiment Signal: Sell
Current Market Cap: C$53.9M
Learn more about QNTM stock on TipRanks’ Stock Analysis page.